

SPR 1642
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Alan Garen *et al.*

Serial No.: 10/030,203

Filed: December 31, 2001

For: Neovascular-Targeted Immunoconjugates

Atty. Docket No.: 006337.00004

Group Art Unit: 1642

Examiner: D. Blanchard

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT AND
CERTIFICATION**

Commissioner of Patents
c/o Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

According to the provisions of 37 C.F.R. § 1.97(d) and (e)(2), applicants submit herewith the fee under § 1.17(p) and the following statement:

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. In compliance with the duty of disclosure set forth in 37 C.F.R. §1.56, submitted herewith for filing in the above referenced patent application is (1) sheet of Form PTO-1449 and copies of each reference. According to the related U.S. application data on the face of the patents, the '844, '833 and '131 patents share a first specification. The other seven patents share a second specification.


Applicant respectfully requests that the Examiner consider these references.

02/11/2005 HBELETE1 00000082 190733 10030203

01 FC:1806 180.00 DA

The Commissioner is authorized to charge \$180.00 to effect entry of this Information Disclosure Statement to Deposit Account 19-0733. Further, the Commissioner is authorized to charge any additional fees which may be required or credit any overpayment to our Deposit Account 19-0733.

Respectfully submitted,



Sarah A. Kagan
Registration No. 32,141

Date: February 9, 2005

By:

Customer No. 22907
Banner & Witcoff, Ltd.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number

10/030,203

Filing Date

December 31, 2001

First Named Inventor

Alan Garen

Group Art Unit

1642

Examiner Name

D. Blanchard

Attorney Docket Number

006337.00004

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231